Publicaciones en colaboración con investigadoras/es de Hospital de Cruces (152)

2024

  1. 2023 EULAR recommendations on imaging in diagnosis and management of crystal-induced arthropathies in clinical practice

    Annals of the Rheumatic Diseases, Vol. 83, Núm. 6, pp. 752-759

2023

  1. Mechanisms and rationale for uricase use in patients with gout

    Nature Reviews Rheumatology, Vol. 19, Núm. 10, pp. 640-649

  2. Outcome reporting in randomized trials in gout: A systematic scoping review from the OMERACT gout working group assessing the uptake of the core outcome set

    Seminars in Arthritis and Rheumatism, Vol. 60

  3. The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease

    Arthritis and Rheumatology, Vol. 75, Núm. 10, pp. 1703-1713

  4. The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease

    Annals of the Rheumatic Diseases, Vol. 82, Núm. 10, pp. 1248-1257

2022

  1. Crystal-Associated Arthritis: Gout

    Synovial Fluid Analysis and the Evaluation of Patients with Arthritis (Springer International Publishing), pp. 91-100

  2. Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the article by Singh and Cleveland

    Annals of the Rheumatic Diseases

  3. Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study

    Clinical Rheumatology, Vol. 41, Núm. 12, pp. 3817-3823

  4. One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study

    Arthritis Research and Therapy, Vol. 24, Núm. 1

  5. Prevalence of gout in the adult general population in Spain: Estimating the proportion of undiagnosed cases

    Joint Bone Spine, Vol. 89, Núm. 1

  6. Prevalence of symptomatic axial osteoarthritis phenotypes in Spain and associated socio-demographic, anthropometric, and lifestyle variables

    Rheumatology International, Vol. 42, Núm. 6, pp. 1085-1096

  7. Prévalence de la goutte dans la population générale en Espagne : une estimation du taux de cas non diagnostiqués

    Revue du Rhumatisme (Edition Francaise), Vol. 89, Núm. 4, pp. 389-395

2021

  1. Prevalence of symptomatic osteoarthritis in Spain: EPISER2016 study

    Reumatologia Clinica, Vol. 17, Núm. 8, pp. 461-470

  2. Which factors predict discordance between a patient and physician on a gout flare?

    Rheumatology (United Kingdom), Vol. 60, Núm. 2, pp. 773-779

2020

  1. 2018 updated European League against Rheumatism evidence-based recommendations for the diagnosis of gout

    Annals of the Rheumatic Diseases, Vol. 79, Núm. 1, pp. 31-38

  2. Fracture risk assessment in the general population in Spain by FRAX® algorithm. EPISER2016 study

    Medicina Clinica, Vol. 154, Núm. 5, pp. 163-170

  3. High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?

    Rheumatology and Therapy, Vol. 7, Núm. 4, pp. 1011-1019

  4. Systematic genetic analysis of early-onset gout: ABCG2 is the only associated locus

    Rheumatology (United Kingdom), Vol. 59, Núm. 9, pp. 2544-2549

2019

  1. Combination urate-lowering therapy in the treatment of gout: What is the evidence?

    Seminars in Arthritis and Rheumatism, Vol. 48, Núm. 4, pp. 658-668

  2. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study

    Arthritis Research and Therapy, Vol. 21, Núm. 1